SRX246

Phase 2Small molecule

AAzevan Pharmaceuticals

SRX246 is one of 34 small molecule programs targeting Anxiety. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

Aggressive BehaviorActive, not recruiting

AnxietyPhase 1

Active, not recruiting

Aggressive BehaviorPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Anxiety

#DrugCompanyPhaseTrials

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

4 2

Celexa

AbbVie

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

4 4

Campral

FForest Laboratories

Preclinical

2 5

Luvox

SSolvay Pharmaceuticals

Preclinical

2 6

Anerem

AAcacia Pharma Ltd

Preclinical

2 7

SRX246

AAzevan Pharmaceuticals

Phase 2

1 8

Sufenta

LLeaf Vertical Inc.

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Andriol

AAuxilium

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Aggressive Behavior

NCT07328529

Clinical

Trials by Indication[1]

Adult1 trial

Study of SRX246 Capsules in Healthy Adult Volunteers

Completed·AAzevan Pharmaceuticals·Phase 1·NCT00910455·49 enrolled

Anxiety1 trial

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Unknown status·AAzevan Pharmaceuticals·Phase 1·NCT02922166·36 enrolled

Aggressive Behavior1 trial

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Not yet recruiting·AAzevan Pharmaceuticals·Phase 2·NCT07328529·80 enrolled

Intermittent Explosive Disorder1 trial

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

Completed·AAzevan Pharmaceuticals·Phase 1/2·NCT02055638·97 enrolled

Efficacy and Safety1 trial

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

Terminated·AAzevan Pharmaceuticals·Phase 2·NCT02733614·33 enrolled

2 more indications

Huntington's Disease1 trial

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

Completed·AAzevan Pharmaceuticals·Phase 2·NCT02507284·106 enrolled

Unspecified1 trial

Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

Completed·AAzevan Pharmaceuticals·Phase 1·NCT01088932·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SRX246. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRX246 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRX246. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azevan Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAzevan Pharmaceuticals

SRX246

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Adult1 trial

Anxiety1 trial

Aggressive Behavior1 trial

Intermittent Explosive Disorder1 trial

Efficacy and Safety1 trial

Huntington's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News